Use of Biologic Therapies With Different Mechanisms of Action (MOA) in the First-line (1L) Treatment of Crohn's Disease (CD) in the US

被引：0

作者：

Huang, Zhongwen ^{[1
]}

Ba, Yi ^{[1
]}

Kamble, Pravin ^{[1
]}

Wang, Song ^{[1
]}

机构：

[1] Takeda, Cambridge, MA USA

来源：

AMERICAN JOURNAL OF GASTROENTEROLOGY | 2021年 / 116卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

S917

引用

页码：S433 / S433

页数：1

共 50 条

[31] Budget Impact of Adding Vedolizumab to a Health Plan Formulary as Another First-Line Biologic Option for Ulcerative Colitis and Crohn's Disease [J].

Wilson, Michele ;

Lucas, Aaron ;

Cameron, Ann ;

Luo, Michelle .

AMERICAN HEALTH AND DRUG BENEFITS, 2018, 11 (05) :253-262

[32] ORCHARD: Osimertinib plus necitumumab in patients (pts) with advanced NSCLC whose disease progressed on first-line (1L) osimertinib [J].

Riess, J. W. ;

De Langen, J. A. ;

Piotrowska, Z. ;

Goldberg, S. B. ;

Goldman, J. W. ;

Okamoto, I. ;

Ponce Aix, S. ;

Teraoka, S. ;

Ambrose, H. ;

Tang, K. H. ;

Maidment, J. ;

Ruiz, B. Merchan ;

Hewson, N. ;

Cosaert, J. ;

Yu, H. A. .

ANNALS OF ONCOLOGY, 2022, 33 :S1571-S1572

[33] The safety and efficacy of ivonescimab in combination with chemotherapy as first-line (1L) treatment for triple-negative breast cancer (TNBC) [J].

Ouyang, Q. ;

Wang, X. ;

Tian, C. ;

Shao, X. ;

Huang, J. ;

Chen, Z-H. ;

Wang, Y. ;

Sun, T. ;

Yi, T. ;

Yu, X. ;

Wang, Z. M. ;

Li, B. ;

Xia, Y. .

ANNALS OF ONCOLOGY, 2024, 35 :S360-S361

[34] The efficacy and safety of ivonescimab with or without ligufalimab in combination with FOLFOXIRI as first-line (1L) treatment for metastatic colorectal cancer (mCRC) [J].

Deng, Y. ;

Liu, H. ;

Xie, L. ;

Zhang, J. ;

Hu, H. ;

Liu, Z. ;

Wang, W. ;

Yu, X. ;

Wang, Z. M. ;

Li, B. ;

Xia, Y. .

ANNALS OF ONCOLOGY, 2024, 35 :S435-S435

[35] US real-world first-line (1L) treatment patterns and outcomes for patients with metastatic urothelial carcinoma (mUC) following maintenance avelumab approval. [J].

Li, Haojie ;

Herms, Lisa ;

Leong, Traci ;

Conkling, Paul R. ;

Franco, Sonia ;

Singhal, Puneet ;

Mamtani, Ronac ;

Bupathi, Manojkumar .

JOURNAL OF CLINICAL ONCOLOGY, 2023, 41

[36] MULTIDIMENSIONAL TREATMENT EFFECT NETWORK META-ANALYSIS TO ESTIMATE SURVIVAL OF THERAPIES FOR PATIENTS WITH FIRST-LINE (1L) ADVANCED OR METASTATIC RENAL CELL CARCINOMA (ARCC) IN FRANCE [J].

Gittfried, A. M., V ;

Lambton, M. ;

Nickel, K. ;

May, J. R. ;

Branchoux, S. ;

Kroep, S. .

VALUE IN HEALTH, 2022, 25 (01) :S25-S25

[37] PREDICTING TREATMENT EFFECTS FROM SURROGATE ENDPOINTS IN FIRST-LINE (1L) METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) [J].

Samjoo, I ;

Disher, T. ;

Castro, E. ;

Ellis, J. ;

Paganelli, S. ;

Nazari, J. ;

Niyazov, A. .

VALUE IN HEALTH, 2023, 26 (12) :S25-S25

[38] Influence of diabetes and congestive heart failure (CHF) on selection of first-line (1L) treatment for metastatic renal cell carcinoma (mRCC) [J].

Gong, J. ;

George, D. ;

Mhatre, S. ;

Lin, S-W. ;

Surinach, A. ;

Wallen, H. ;

Vohra, R. ;

Simpson, J. ;

Ogale, S. ;

Pal, S. K. .

ANNALS OF ONCOLOGY, 2016, 27

[39] Real-world treatment characteristics for first-line therapy (1L) of advanced hepatocellular carcinoma (HCC) in Canada and Europe. [J].

Gill, Sharlene ;

Jaffe, Dena H. ;

DeCongelio, Marc ;

DuBell, Arnold N. ;

Shi, Jing ;

Wisniewski, Tami ;

Thompson, Gwilym .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)

[40] Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn's disease [J].

Singh, S. ;

Fumery, M. ;

Sandborn, W. J. ;

Murad, M. H. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 48 (04) :394-409

← 1 2 3 4 5 →